OptiKira Pursuing A Novel Small-Molecule Approach To Retinitis Pigmentosa
An early-stage, small-molecule approach to the treatment of retinitis pigmentosa being developed by US biotech OptiKira may have potential benefits over more advanced gene and cell therapies for the blindness-causing condition.
You may also be interested in...
Initial VC and institutional funding from a French syndicate will support further drug development at Paris-based Horama, which aims to put two targeted gene therapies for hereditary retinitis pigmentosa in the clinic by 2018.
Philadelphia-based Spark Therapeutics has acquired private, Irish gene therapy company, Genable Technologies, for $6m in cash and 265,000 shares of Spark common stock.
The UK's next-generation engineered T-cell immunotherapy company Autolus Ltd. has raised £40m ($56m) in a Series B financing that includes the first investment by the new UK investment firm, Perceptive Bioscience Investments Ltd., and funding from Woodford Investment Management LLP. The round brings Autolus's total funding to a respectable £70m in less than two years.